Last reviewed · How we verify
Poliomyelitis Vaccine inactivated
This vaccine works by introducing inactivated poliovirus to the body, stimulating an immune response to fight poliovirus infection.
This vaccine works by introducing inactivated poliovirus to the body, stimulating an immune response to fight poliovirus infection. Used for Prevention of poliomyelitis.
At a glance
| Generic name | Poliomyelitis Vaccine inactivated |
|---|---|
| Also known as | IMOVAX Polio ™ |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The inactivated poliovirus vaccine (IPV) is a type of vaccine that contains killed poliovirus. When administered, it triggers an immune response, producing antibodies that can recognize and neutralize the poliovirus, providing protection against polio infection.
Approved indications
- Prevention of poliomyelitis
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poliomyelitis Vaccine inactivated CI brief — competitive landscape report
- Poliomyelitis Vaccine inactivated updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI